Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Figure 2: changes in growth hormone expression in a (A) dose-dependent manner and (B) a time-dependent manner
Focus on body composition (Inbody at Affinity offices), energy levels, and habits rather than just pounds lost
Add to cart Quick View
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
